News
Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...
After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...
US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...
Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results